GRI Bio (GRI) Operating Expenses (2020 - 2026)
GRI Bio (GRI) posted quarterly Operating Expenses of $2.0 million for Q1 2026, down 34.35% year-over-year from $3.1 million in Q1 2025, and down 24.81% quarter-over-quarter from $2.7 million in Q4 2025.
GRI Bio (GRI) Operating Expenses (2020 - 2026) Analysis & Trends
GRI Bio's Operating Expenses history runs 7 years deep, the most recent figure standing at $2.0 million for Q1 2026.
- In Q1 2026, Operating Expenses fell 34.35% year-over-year to $2.0 million; the TTM figure through Mar 2026 stood at $10.9 million (up 16.36% YoY), while the FY2025 annual figure was $12.0 million, up 45.44% from the prior year.
- Operating Expenses for Q1 2026 stood at $2.0 million, down from $2.7 million in the prior quarter.
- The five-year high for Operating Expenses was $5.9 million in Q2 2023, with the low at $186000.0 in Q3 2022.
- The 5-year median for Operating Expenses is $2.1 million (2024), against an average of $2.3 million.
- The sharpest annual moves came in 2022 and 2023: Operating Expenses plunged 91.82% in 2022, then soared 3039.68% in 2023.
- GRI Bio's Operating Expenses stood at $1.7 million in 2022, then rose by 21.54% to $2.0 million in 2023, then slipped by 3.55% to $2.0 million in 2024, then soared by 36.34% to $2.7 million in 2025, then slipped by 24.81% to $2.0 million in 2026.
- Business Quant data shows GRI's Operating Expenses at $2.0 million in Q1 2026, $2.7 million in Q4 2025, and $3.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | GRI Bio | 3.07 Mn | 3.07 Mn | - | 1.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.00 Mn |
| Dec 31, 2025 | 2.66 Mn |
| Sep 30, 2025 | 3.37 Mn |
| Jun 30, 2025 | 2.90 Mn |
| Mar 31, 2025 | 3.05 Mn |
| Dec 31, 2024 | 1.95 Mn |
| Sep 30, 2024 | 2.13 Mn |
| Jun 30, 2024 | 2.26 Mn |
| Mar 31, 2024 | 1.90 Mn |
| Dec 31, 2023 | 2.03 Mn |
| Sep 30, 2023 | 2.44 Mn |
| Jun 30, 2023 | 5.93 Mn |
| Mar 31, 2023 | 988,000.00 |
| Dec 31, 2022 | 1.67 Mn |
| Sep 30, 2022 | 186,000.00 |
| Jun 30, 2022 | 189,000.00 |
| Mar 31, 2022 | 2.63 Mn |
| Dec 31, 2021 | 3.09 Mn |
| Sep 30, 2021 | 1.25 Mn |
| Jun 30, 2021 | 2.31 Mn |